Recombinant human tissue kallikrein
PreclinicalSmall molecule
Recombinant human tissue kallikrein is one of 2 small molecule programs targeting Acute Stroke. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Acute Stroke
#DrugCompanyPhaseTrials
1Repatha
AmgenApproved
Recombinant human tissue kallikrein
DDiaMedica Therapeutics Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDiaMedica Therapeutics Inc